Development and evaluation of a tetravalent botulinum vaccine
Botulinum neurotoxins (BoNTs) are the most toxic known proteins. Naturally occurring botulism in humans is caused by botulinum serotypes A, B, E, and F. Vaccination is an effective strategy to prevent botulism. In this study, a tetravalent botulinum vaccine (TBV) that can prevent serotypes A, B, E,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2048621 |
| _version_ | 1827806505051619328 |
|---|---|
| author | Dan-Yang Shi Fu-Jia Liu Zhi-Ying Li Yun-Yun Mao Jian-Sheng Lu Rong Wang Xiao-Bin Pang Yun-Zhou Yu Zhi-Xin Yang |
| author_facet | Dan-Yang Shi Fu-Jia Liu Zhi-Ying Li Yun-Yun Mao Jian-Sheng Lu Rong Wang Xiao-Bin Pang Yun-Zhou Yu Zhi-Xin Yang |
| author_sort | Dan-Yang Shi |
| collection | DOAJ |
| description | Botulinum neurotoxins (BoNTs) are the most toxic known proteins. Naturally occurring botulism in humans is caused by botulinum serotypes A, B, E, and F. Vaccination is an effective strategy to prevent botulism. In this study, a tetravalent botulinum vaccine (TBV) that can prevent serotypes A, B, E, and F was developed using the C-terminal receptor-binding domain of BoNT (Hc) as an antigen. To develop a suitable vaccine formulation, in vitro binding experiments of antigens and aluminum adjuvant in different buffers, and in vivo experiments of TBV at different antigen concentrations, were conducted. Our results showed that the optimal vaccine formulation buffer was a pH 6.0 phosphate buffer, and the suitable antigen concentration was 40 or 80 µg/ml of each antigen. A pilot-scale TBV was then prepared and evaluated for immunogenicity and stability. The results showed that TBV could elicit strong protective efficacy against each BoNT in mice, and remain effective after two years of storage at 4ºC, indicating that the preparation was stable and highly effective. Adsorption experiments also showed that the antigens could be well adsorbed by the aluminum adjuvant after 2 years of storage. Our results provide valuable experimental data supporting the development of a tetravalent botulinum vaccine, which is a promising candidate for the prevention of botulinum serotypes A, B, E, and F. |
| first_indexed | 2024-03-11T21:42:06Z |
| format | Article |
| id | doaj.art-d13fe55a50ff4bd2a4049cbf8dc83890 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:06Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-d13fe55a50ff4bd2a4049cbf8dc838902023-09-26T13:19:05ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20486212048621Development and evaluation of a tetravalent botulinum vaccineDan-Yang Shi0Fu-Jia Liu1Zhi-Ying Li2Yun-Yun Mao3Jian-Sheng Lu4Rong Wang5Xiao-Bin Pang6Yun-Zhou Yu7Zhi-Xin Yang8Beijing Institute of BiotechnologyBeijing Institute of BiotechnologyBeijing Institute of BiotechnologyBeijing Institute of BiotechnologyBeijing Institute of BiotechnologyBeijing Institute of BiotechnologyHenan UniversityBeijing Institute of BiotechnologyBeijing Institute of BiotechnologyBotulinum neurotoxins (BoNTs) are the most toxic known proteins. Naturally occurring botulism in humans is caused by botulinum serotypes A, B, E, and F. Vaccination is an effective strategy to prevent botulism. In this study, a tetravalent botulinum vaccine (TBV) that can prevent serotypes A, B, E, and F was developed using the C-terminal receptor-binding domain of BoNT (Hc) as an antigen. To develop a suitable vaccine formulation, in vitro binding experiments of antigens and aluminum adjuvant in different buffers, and in vivo experiments of TBV at different antigen concentrations, were conducted. Our results showed that the optimal vaccine formulation buffer was a pH 6.0 phosphate buffer, and the suitable antigen concentration was 40 or 80 µg/ml of each antigen. A pilot-scale TBV was then prepared and evaluated for immunogenicity and stability. The results showed that TBV could elicit strong protective efficacy against each BoNT in mice, and remain effective after two years of storage at 4ºC, indicating that the preparation was stable and highly effective. Adsorption experiments also showed that the antigens could be well adsorbed by the aluminum adjuvant after 2 years of storage. Our results provide valuable experimental data supporting the development of a tetravalent botulinum vaccine, which is a promising candidate for the prevention of botulinum serotypes A, B, E, and F.http://dx.doi.org/10.1080/21645515.2022.2048621botulinum neurotoxintetravalent botulinum vaccinealuminum adjuvantformulation |
| spellingShingle | Dan-Yang Shi Fu-Jia Liu Zhi-Ying Li Yun-Yun Mao Jian-Sheng Lu Rong Wang Xiao-Bin Pang Yun-Zhou Yu Zhi-Xin Yang Development and evaluation of a tetravalent botulinum vaccine Human Vaccines & Immunotherapeutics botulinum neurotoxin tetravalent botulinum vaccine aluminum adjuvant formulation |
| title | Development and evaluation of a tetravalent botulinum vaccine |
| title_full | Development and evaluation of a tetravalent botulinum vaccine |
| title_fullStr | Development and evaluation of a tetravalent botulinum vaccine |
| title_full_unstemmed | Development and evaluation of a tetravalent botulinum vaccine |
| title_short | Development and evaluation of a tetravalent botulinum vaccine |
| title_sort | development and evaluation of a tetravalent botulinum vaccine |
| topic | botulinum neurotoxin tetravalent botulinum vaccine aluminum adjuvant formulation |
| url | http://dx.doi.org/10.1080/21645515.2022.2048621 |
| work_keys_str_mv | AT danyangshi developmentandevaluationofatetravalentbotulinumvaccine AT fujialiu developmentandevaluationofatetravalentbotulinumvaccine AT zhiyingli developmentandevaluationofatetravalentbotulinumvaccine AT yunyunmao developmentandevaluationofatetravalentbotulinumvaccine AT jianshenglu developmentandevaluationofatetravalentbotulinumvaccine AT rongwang developmentandevaluationofatetravalentbotulinumvaccine AT xiaobinpang developmentandevaluationofatetravalentbotulinumvaccine AT yunzhouyu developmentandevaluationofatetravalentbotulinumvaccine AT zhixinyang developmentandevaluationofatetravalentbotulinumvaccine |